{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T10:14:24Z","timestamp":1770286464400,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s40272-020-00392-5","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T01:02:31Z","timestamp":1586912551000},"page":"251-262","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Interleukin-1 Blockade in Systemic Juvenile Idiopathic Arthritis"],"prefix":"10.1007","volume":"22","author":[{"given":"Manel","family":"Mejbri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katerina","family":"Theodoropoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolando","family":"Cimaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,15]]},"reference":[{"key":"392_CR1","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/nrrheum.2011.68","volume":"7","author":"ED Mellins","year":"2011","unstructured":"Mellins ED, Macaubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol. 2011;7:416\u201326.","journal-title":"Nat Rev Rheumatol"},{"key":"392_CR2","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1084\/jem.20050473","volume":"201","author":"V Pascual","year":"2005","unstructured":"Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005;201:1479\u201386.","journal-title":"J Exp Med"},{"key":"392_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1146\/annurev.immunol.021908.132715","volume":"27","author":"F Martinon","year":"2009","unstructured":"Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Ann Rev Immunol. 2009;27:229\u201365.","journal-title":"Ann Rev Immunol"},{"key":"392_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","volume":"10","author":"F Martinon","year":"2002","unstructured":"Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002;10:417\u201326.","journal-title":"Mol Cell"},{"key":"392_CR5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/ncprheum0681","volume":"4","author":"LD Church","year":"2008","unstructured":"Church LD, Cook GP, McDermott MF. Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol. 2008;4:34\u201342.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"392_CR6","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/art.38296","volume":"66","author":"SJ Vastert","year":"2014","unstructured":"Vastert SJ, de Jager W, Noordman BJ, Holzinger D, Kuis W, Prakken BJ, et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol. 2014;66:1034\u201343.","journal-title":"Arthritis Rheumatol"},{"key":"392_CR7","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1136\/ard.2010.134254","volume":"70","author":"P Quartier","year":"2011","unstructured":"Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70:747\u201354.","journal-title":"Ann Rheum Dis"},{"key":"392_CR8","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1517\/14712598.2010.532785","volume":"10","author":"JF Swart","year":"2010","unstructured":"Swart JF, Barug D, Mohlmann M, Wulffraat NM. The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis. Expert Opin Biol Ther. 2010;10:1743\u201352.","journal-title":"Expert Opin Biol Ther"},{"key":"392_CR9","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1136\/ard.2007.076034","volume":"67","author":"T Lequerre","year":"2008","unstructured":"Lequerre T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2008;67:302\u20138.","journal-title":"Ann Rheum Dis"},{"key":"392_CR10","unstructured":"European Medicines Agency. Summary of product characteristics\u2014kineret. https:\/\/www.ema.europa.eu\/documents\/product-information\/kineret-epar-product-information_en.pdf. Accessed 19 June 2019"},{"key":"392_CR11","first-page":"2071","volume":"31","author":"JW Verbsky","year":"2004","unstructured":"Verbsky JW, White AJ. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2004;31:2071\u20135.","journal-title":"J Rheumatol"},{"key":"392_CR12","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/art.30128","volume":"63","author":"PA Nigrovic","year":"2011","unstructured":"Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, et al. Anakinra as first line disease modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicentre series. Arthritis Rheumatol. 2011;63:545\u201355.","journal-title":"Arthritis Rheumatol"},{"key":"392_CR13","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.3899\/jrheum.141567","volume":"42","author":"M Pardeo","year":"2015","unstructured":"Pardeo M, Pires Marafon D, Insalaco A, Bracaglia C, Nicolai R, Messia V, et al. Anakinra in systemic juvenile idiopathic arthritis: a single-center experience. J Rheumatol. 2015;42:1523\u20137.","journal-title":"J Rheumatol"},{"key":"392_CR14","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1007\/s10067-018-4297-6","volume":"37","author":"HE Baris","year":"2018","unstructured":"Baris HE, Anderson E, Sozeri B, Dedeoglu F. Impact of biologics on disease course in systemic onset juvenile idiopathic arthritis. Clin Rheumatol. 2018;37:3263\u201373.","journal-title":"Clin Rheumatol"},{"key":"392_CR15","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/rheumatology\/key262","volume":"58","author":"L Kearsley-Fleet","year":"2019","unstructured":"Kearsley-Fleet L, Beresford MW, Davies R, De Cock D, Baildam E, Foster HE, et al. Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra. Rheumatology. 2019;58:94\u2013102.","journal-title":"Rheumatology"},{"key":"392_CR16","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1002\/art.40865","volume":"71","author":"NM Ter Haar","year":"2019","unstructured":"Ter Haar NM, van Dijkhuizen EHP, Swart JF, van Royen-Kerkhof A, El Idrissi A, Leek AP, et al. Treat-to-target using first-line recombinant interleukin 1 receptor antagonist monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five year follow-up study. Arthritis Rheumatol. 2019;71:1163\u201373.","journal-title":"Arthritis Rheumatol"},{"key":"392_CR17","unstructured":"European Medicines Agency. Summary of product characteristics\u2014Ilaris. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ilaris. Accessed 21 June 2019"},{"key":"392_CR18","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","volume":"367","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2396\u2013406.","journal-title":"N Engl J Med"},{"key":"392_CR19","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1002\/art.33342","volume":"64","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Quartier P, Wulffraat N, Woo P, Ravelli A, Mouy R, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheumatol. 2012;64:557\u201367.","journal-title":"Arthritis Rheumatol"},{"key":"392_CR20","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1136\/annrheumdis-2018-213150","volume":"77","author":"N Ruperto","year":"2018","unstructured":"Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat NM, Horneff G, et al. Canakinumab in patients with systemic juvenile idiopathic arthritis active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. Ann Rheum Dis. 2018;77:1710\u20139.","journal-title":"Ann Rheum Dis"},{"key":"392_CR21","first-page":"668","volume":"36","author":"E Feist","year":"2018","unstructured":"Feist E, Quartier P, Fautrel B, Schneider R, Sfriso P, Efthimiou P, et al. Efficacy and safety of canakinumab in patients with Still\u2019s disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups. Clin Exp Rheumatol. 2018;36:668\u201375.","journal-title":"Clin Exp Rheumatol"},{"key":"392_CR22","doi-asserted-by":"publisher","first-page":"E1898","DOI":"10.3390\/ijms20081898","volume":"20","author":"A Bettiol","year":"2019","unstructured":"Bettiol A, Lopalco G, Emmi G, Cantarini L, Urban ML, Vitale A, et al. Unveiling the efficacy, safety, and tolerability of anti-Interleukin-1 treatment in monogenic and multifactorial autoinflammatory diseases. Int J Mol Sci. 2019;20:E1898.","journal-title":"Int J Mol Sci"},{"key":"392_CR23","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.2147\/DDDT.S114532","volume":"12","author":"N Toplak","year":"2018","unstructured":"Toplak N, Blazina \u0160, Avcin T. The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives. Drug Des Dev Ther. 2018;12:1633\u201343.","journal-title":"Drug Des Dev Ther"},{"key":"392_CR24","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1007\/s10067-018-4119-x","volume":"37","author":"J Sota","year":"2018","unstructured":"Sota J, Vitale A, Insalaco A, Sfriso P, Lopalco G, Emmi G, et al. Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. Clin Rheumatol. 2018;37:2233\u201340.","journal-title":"Clin Rheumatol"},{"key":"392_CR25","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/acr.23277","volume":"70","author":"GS Schulert","year":"2018","unstructured":"Schulert GS, Minoia F, Bohnsack J, Cron RQ, Hashad S, Kon\u00e9-Paut I, et al. Effect of biologic therapy on clinical and laboratory features of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis. Arthritis Care Res. 2018;70:409\u201319.","journal-title":"Arthritis Care Res"},{"key":"392_CR26","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/art.39407","volume":"68","author":"AA Grom","year":"2016","unstructured":"Grom AA, Ilowite NT, Pascual V, Brunner HI, Martini A, Lovell D, et al. Rate and clinical presentation of macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with canakinumab. Arthritis Rheumatol. 2016;68:218\u201328.","journal-title":"Arthritis Rheumatol"},{"key":"392_CR27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12969-019-0309-6","volume":"17","author":"O Halyabar","year":"2019","unstructured":"Halyabar O, Chang MH, Schoettler ML, Schwartz MA, Baris EH, Benson LA, et al. Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome. Pediatr Rheumatol. 2019;17:7.","journal-title":"Pediatr Rheumatol"},{"key":"392_CR28","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1002\/art.38042","volume":"65","author":"DJ Lovell","year":"2013","unstructured":"Lovell DJ, Giannini EH, Reiff AO, Kimura Y, Li S, Hashkes PJ, et al. Long term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum. 2013;65:2486\u201396.","journal-title":"Arthritis Rheum"},{"key":"392_CR29","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1002\/art.38699","volume":"66","author":"NT Ilowite","year":"2014","unstructured":"Ilowite NT, Prather K, Lokhnygina Y, Schanberg LE, Elder M, Milojevic D, et al. Randomized, double blind, placebo controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2014;66:2570\u20139.","journal-title":"Arthritis Rheumatol"},{"key":"392_CR30","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/rheumatology\/kev382","volume":"55","author":"S Tarp","year":"2016","unstructured":"Tarp S, Amarilyo G, Foeldvari I, Christensen R, Woo JM, Cohen N, et al. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials. Rheumatology (Oxford). 2016;55:669\u201379.","journal-title":"Rheumatology (Oxford)"},{"key":"392_CR31","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1002\/art.38092","volume":"65","author":"S Ringold","year":"2013","unstructured":"Ringold S, Weiss PF, Beukelman T, DeWitt EM, Ilowite NT, Kimura Y, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheumatol. 2013;65:2499\u2013512.","journal-title":"Arthritis Rheumatol"},{"key":"392_CR32","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2147\/AHMT.S109495","volume":"8","author":"S Grevich","year":"2017","unstructured":"Grevich S, Shenoi S. Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition. Adolesc Health Med Ther. 2017;8:125\u201335.","journal-title":"Adolesc Health Med Ther"},{"key":"392_CR33","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40272-016-0186-0","volume":"18","author":"\u0160 Blazina","year":"2016","unstructured":"Blazina \u0160, Markelj G, Avramovi\u010d MZ, Toplak N, Av\u010din T. Management of juvenile idiopathic arthritis: a clinical guide. Paediatr Drugs. 2016;18:397\u2013412.","journal-title":"Paediatr Drugs"},{"key":"392_CR34","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1177\/1740774518761367","volume":"15","author":"PA Nigrovic","year":"2018","unstructured":"Nigrovic PA, Beukelman T, Tomlinson G, Feldman BM, Schanberg LE, Kimura Y, Childhood Arthritis, and Rheumatology Research Alliance Systemic Juvenile Idiopathic Arthritis Consensus Treatment Plan Workgroup. Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST). Clin Trials. 2018;15:268\u201377.","journal-title":"Clin Trials"},{"key":"392_CR35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12969-018-0224-2","volume":"16","author":"CH Hinze","year":"2018","unstructured":"Hinze CH, Holzinger D, Lainka E, Haas JP, Speth F, Kallinich T, et al. Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany. Pediatr Rheumatol. 2018;16:7.","journal-title":"Pediatr Rheumatol"},{"key":"392_CR36","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/art.23437","volume":"58","author":"M Gattorno","year":"2008","unstructured":"Gattorno M, Piccini A, Lasigli\u00e8 D, Tassi S, Brisca G, Carta S, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheumatol. 2008;58:1505\u201315.","journal-title":"Arthritis Rheumatol"},{"key":"392_CR37","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1136\/annrheumdis-2019-216040","volume":"78","author":"VE Saper","year":"2019","unstructured":"Saper VE, Chen G, Deutsch GH, Guillerman RP, Birgmeier J, Jagadeesh K, et al. Emergent high fatality lung disease in systemic juvenile arthritis. Ann Rheum Dis. 2019;78:1722\u201331.","journal-title":"Ann Rheum Dis"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-020-00392-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-020-00392-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-020-00392-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T07:52:00Z","timestamp":1618473120000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-020-00392-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,15]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["392"],"URL":"https:\/\/doi.org\/10.1007\/s40272-020-00392-5","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,15]]},"assertion":[{"value":"15 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors received no funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors, MM, KT, MH, and RC, declare they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}